Association between relative mtDNA copy number and colorectal cancer risk
| All cases | Incident casesb | Prevalent casesb | |||||
|---|---|---|---|---|---|---|---|
| mtDNA levela | No. of controls | N | ORc (95% CI) | N | ORc (95% CI) | N | ORc (95% CI) |
| 1st quartile | 219 | 130 | 1.81 (1.13–2.89) | 61 | 3.51 (1.60–7.68) | 69 | 1.32 (0.77–2.26) |
| 2nd quartile | 219 | 59 | 1.00 | 22 | 1.00 | 37 | 1.00 |
| 3rd quartile | 219 | 74 | 1.40 (0.86–2.29) | 27 | 1.58 (0.69–3.62) | 47 | 1.20 (0.68–2.11) |
| 4th quartile | 217 | 159 | 3.40 (2.15–5.36) | 58 | 4.66 (2.15–10.11) | 101 | 3.37 (2.02–5.62) |
| P value for curvilinearity | <0.0001 | <0.0001 | <0.0001 | ||||
↵aQuartile levels are based on gender-specific cutoff values: men ≤ 0.36, 0.37–0.47, 0.48–0.62, >0.62; women ≤ 0.40, 0.41–0.54, 0.55–0.71, >0.71.
↵bBlood samples were collected 28.9 (SD = 26.4) months before cancer diagnosis for incident cases and 13.1 (SD = 12.5) months after cancer diagnosis for prevalent cancer cases.
↵cAdjusted for age at sample collection, gender, BMI, smoking status, alcohol drinking, weekly moderate or vigorous physical activity, history of diabetes, and batch number for mtDNA copy number assay.